目的 探討人免疫球蛋白聯(lián)合拉氧頭孢鈉治療新生兒感染性肺炎的療效觀察。方法 選取2019年11月—2020年12月南陽市中心醫(yī)院收治的170例新生兒感染性肺炎患兒，隨機(jī)分為對(duì)照組和治療組，每組各85例。對(duì)照組患兒靜脈滴注注射用拉氧頭孢鈉，每天30 mg/kg，間隔12 h滴注1次，1次滴注30 min以上。治療組在對(duì)照組基礎(chǔ)上靜脈滴注凍干靜注人免疫球蛋白（pH 4），首次劑量400 mg/kg，1次/d。兩組患兒均治療5 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀好轉(zhuǎn)時(shí)間、免疫能力，及血清炎癥因子超敏C反應(yīng)蛋白（hs-CRP）、降鈣素原（PCT）、白細(xì)胞介素6（IL-6）和IL-10水平。結(jié)果 治療后，治療組臨床有效率為96.47%，明顯高于對(duì)照組的87.06%（P<0.05）。治療后，治療組臨床癥狀好轉(zhuǎn)時(shí)間明顯短于對(duì)照組（P<0.05）。治療后，兩組免疫球蛋白G（IgG）、IgG1、IgG2、IgG3和IgG4水平升高（P<0.05），且治療組明顯高于對(duì)照組（P<0.05）。治療后，兩組hs-CRP、PCT、IL-6和IL-10水平顯著降低（P<0.05），且治療組低于對(duì)照組（P<0.05）。結(jié)論 凍干靜注人免疫球蛋白聯(lián)合抗生素拉氧頭孢鈉治療新生兒感染性肺炎療效顯著，能夠迅速改善患兒體征和臨床癥狀，增強(qiáng)免疫功能，降低炎癥水平。

Objective To investigate the effect of lyophilized human immunoglobulin combined with latamoxef sodium in treatment of neonatal infectious pneumonia. Methods Children (170 cases) with infectious pneumonia in Nanyang Central Hospital from November 2019 to December 2020 were randomly divided into control and treatment groups, and each group had 85 cases. Children in the control group were iv administered with Latamoxef Sodium for injection, 30 mg/kg daily, once at intervals of 12 h, more than 30 min at a time. Children in the treatment group were iv administered with Human Immunoglobulin (pH 4) for Intravenous Injection, the first dose was 400 mg/kg, once daily. Children in two groups were treated for 5 d. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms, the immune ability, and the serum inflammatory factors of hs-CRP, PCT, IL-6 and IL-10 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 96.47%, which was significantly higher than 87.06% in the control group (P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the levels of immunoglobulin G (IgG), IgG1, IgG2, IgG3 and IgG4 in both groups were increased (P < 0.05), and those in treatment group were significantly higher than those in control group (P < 0.05). After treatment, the levels of HS-CRP, PCT, IL-6 and IL-10 in both groups were significantly decreased (P < 0.05), and those in treatment group were lower than those in control group (P < 0.05). Conclusion Lyophilized human immunoglobulin combined with latamoxef sodium is effective in treatment of neonatal infectious pneumonia can quickly improve the physical signs and clinical symptoms, enhance the immune function and reduce the level of inflammation.

R974;R985

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（LHGJ20190898）